Analysts expect Dova Pharmaceuticals Inc (NASDAQ:DOVA) to report $5.68 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Dova Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.86 million and the highest estimate coming in at $6.63 million. The firm is expected to issue its next earnings results on Thursday, February 21st.
According to Zacks, analysts expect that Dova Pharmaceuticals will report full year sales of $12.78 million for the current fiscal year, with estimates ranging from $9.91 million to $14.00 million. For the next fiscal year, analysts forecast that the company will post sales of $68.08 million, with estimates ranging from $63.00 million to $74.92 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.12. The firm had revenue of $2.93 million for the quarter, compared to the consensus estimate of $2.66 million.
DOVA has been the topic of several research reports. BidaskClub cut shares of Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, November 2nd. Zacks Investment Research cut shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 30th. Leerink Swann cut their price objective on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 4th. Finally, Raymond James initiated coverage on shares of Dova Pharmaceuticals in a research report on Wednesday, August 29th. They issued an “outperform” rating and a $44.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Dova Pharmaceuticals presently has an average rating of “Hold” and an average price target of $33.20.
Shares of NASDAQ DOVA opened at $16.89 on Friday. The firm has a market cap of $530.20 million, a PE ratio of -12.06 and a beta of 0.87. Dova Pharmaceuticals has a twelve month low of $16.63 and a twelve month high of $37.00. The company has a current ratio of 13.19, a quick ratio of 13.14 and a debt-to-equity ratio of 0.17.
In other news, CEO Alex Sapir acquired 21,700 shares of the stock in a transaction dated Tuesday, August 14th. The shares were bought at an average cost of $22.83 per share, for a total transaction of $495,411.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 55.50% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp raised its position in Dova Pharmaceuticals by 17.5% in the 1st quarter. Northern Trust Corp now owns 64,161 shares of the company’s stock valued at $1,740,000 after purchasing an additional 9,569 shares in the last quarter. BlackRock Inc. raised its position in Dova Pharmaceuticals by 12.5% in the 1st quarter. BlackRock Inc. now owns 648,614 shares of the company’s stock valued at $17,591,000 after purchasing an additional 71,815 shares in the last quarter. JPMorgan Chase & Co. raised its position in Dova Pharmaceuticals by 148.6% in the 1st quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock valued at $145,000 after purchasing an additional 3,195 shares in the last quarter. Jane Street Group LLC acquired a new stake in Dova Pharmaceuticals in the 1st quarter valued at about $220,000. Finally, Commonwealth Equity Services LLC acquired a new stake in Dova Pharmaceuticals in the 2nd quarter valued at about $215,000. Institutional investors own 36.64% of the company’s stock.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Read More: Moving Average (MA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.